Case Details
- Citation: [2016] SGHC 275
- Case Title: Goh Seng Heng v RSP Investments and others and another matter
- Court: High Court of the Republic of Singapore
- Date of Decision: 12 December 2016
- Judge(s): Lai Siu Chiu SJ
- Coram: Lai Siu Chiu SJ
- Case Numbers: Suit No 546 of 2015 (Summons No 1124 of 2016) and Suit No 111 of 2016 (Summonses Nos 554, 754 and 934 of 2016)
- Procedural Posture: Applications for injunctions and/or Mareva relief; setting aside applications; related appeals to the Court of Appeal (with subsequent outcomes noted in the LawNet editorial note)
- Plaintiff/Applicant: Goh Seng Heng (“Dr Goh”)
- Defendant/Respondent: RSP Investments and others and another matter
- Legal Areas: Civil Procedure — Injunctions; Civil Procedure — Mareva injunctions
- Key Parties (High-level): Aesthetic Medical Partners Pte Ltd (“Company”); Aesthetic Medical Holdings Pte Ltd (“AMH”); PPP Investments Pte Ltd (“PPP Investments”); Quikglow Pte Ltd (formerly Dr Michelle Goh Pte Ltd); Motcombe Holdings Limited; RSP Investments; Terence Loh and Nelson Loh; Justin Demetrio Reis and Peter Anthony Reis; Lee Kin Yun; Koh Mui Lee; Melissa Goh
- Counsel (Suit No 546 of 2015 / first, second, third defendants in Suit No 111 of 2016): Goh Chee Hsien, Joel Lim Siok Khoon, Ong Pei Ching, Tan Gim Hai Adrian and Yeoh Jean Wern (Morgan Lewis Stamford LLC) for the plaintiff in Suit No 546 of 2015 and the first, second and third defendants in Suit No 111 of 2016
- Counsel (Suit No 546 of 2015 / first, second, third defendants): Suresh S/O Damodara (Damodara Hazra LLP) for the first, second and third defendants in Suit No 546 of 2015
- Counsel (Suit No 546 of 2015 / fourth, fifth, sixth defendants): Pereira Kenetth Jerald, Sujatha Selvakumar and Wee Jia Min (Aldgate Chambers LLC) for the fourth, fifth and sixth defendants in Suit No 546 of 2015
- Counsel (Suit No 111 of 2016 / first and second plaintiffs): N Sreenivasan SC, Rajaram Muralli Raja, Heng Wui-Kee Andrew, Lim Jie, Nicole Cheah Shen-Li and Tan Kai Ning Claire (Straits Law Practice LLC) for the first and second plaintiffs in Suit No 111 of 2016
- Related Appeals (as per LawNet editorial note): Civil Appeal No 114 of 2016 (plaintiff in Suit No 546 of 2015) dismissed; Civil Appeals Nos 115 and 116 of 2016 (defendants in Suit No 111 of 2016) heard 13 April 2017; CA 115/2016 allowed and orders made for CA 116/2016; no written grounds rendered
- Judgment Length: 18 pages, 10,626 words
- Statutes Referenced: Companies Act (including provisions on fraudulent trading and related corporate remedies)
- Cases Cited: [2016] SGHC 275 (as provided in metadata; the excerpt supplied does not list further authorities)
Summary
This High Court decision arose from an intense shareholder and investor dispute involving a Singapore company that operates aesthetic laser services and skincare-related products and services. The litigation was not merely about underlying contractual and fiduciary claims; it also concerned urgent interlocutory relief—specifically injunctions to preserve the status quo in corporate governance and Mareva-type freezing relief to prevent dissipation of assets. The court addressed multiple applications brought in two related suits, reflecting competing narratives of wrongdoing, control, and commercial conduct.
In the portion of the judgment provided, the court records that it dismissed Dr Goh’s application for an injunction restraining certain defendants from calling meetings to alter the share capital of the Company (including allotting and/or issuing shares and voting to alter share capital). The court also describes the earlier grant of a Mareva injunction in the AM group’s suit, and the grant of an injunction restraining Dr Goh and Michelle from competing through Quikglow. The decision thus sits at the intersection of corporate control disputes and the procedural standards governing urgent equitable relief.
What Were the Facts of This Case?
The Company, Aesthetic Medical Partners Pte Ltd, was incorporated in August 2008 and operates aesthetic laser services and skincare-related products and services. Dr Goh is a dermatologist by training and was the managing director and remains a shareholder. His daughters, Dr Michelle Goh and Melissa Goh, were directors of the Company, with Michelle also remaining a shareholder. Together with Dr Goh’s company, Dr Goh Seng Heng Pte Ltd, Dr Goh and Michelle held 13.31% of the shares in the Company.
RSP Investments (“RSP”) is a Cayman Islands company and is a shareholder of the Company. RSP is controlled by Terence Loh and his cousin Nelson Loh. Another key actor is Motcombe Holdings Limited (“Motcombe”), a BVI company which until 23 July 2014 was a shareholder of the Company. Motcombe is owned and/or controlled by Justin Demetrio Reis and his father Peter Anthony Reis. A further shareholder, Lucy (Wang Xiaopu), was also a defendant in the 2015 suit but was later removed from the action. Between the six defendants and Lucy, they held and/or controlled 63.47% of the Company’s shares, while other shareholders existed whose voting arrangements were relevant to the dispute.
The litigation is best understood as a power struggle over corporate control and governance. In December 2013, a fund called Lion Rock Capital (“Lion Rock”) wanted to invest in the Company. Nelson, as a director of RSP, was tasked with structuring a deal between the Company and Lion Rock. Dr Goh alleged that Nelson, without board approval, sought to arrange for Lion Rock to buy Nelson’s and Justin’s shares. This allegation catalysed disagreements between Dr Goh, RSP, and Justin.
On 24 January 2014, the parties reached a Settlement Agreement. Under it, Motcombe agreed to transfer 18,696 of its 62,319 shares to RSP (which already held 50,000 shares). RSP also bought additional shares by exercising an option to purchase granted to Justin, after which the option was transferred to RSP. As a result, RSP owned 101,591 shares. The Settlement Agreement also included governance-related arrangements: RSP, Terence, and Nelson would appoint Dr Goh or Michelle as their proxies or representatives at general meetings and sign resolutions on their behalf. Similarly, Justin and Peter agreed to appoint Dr Goh and Michelle as proxies and representatives at general meetings and to sign resolutions on their behalf.
Further, Motcombe was to transfer its remaining shares (after deducting the 18,696 transferred to RSP) to a “Motcombe transferee” acceptable to Dr Goh; Peter became that transferee in February 2014. Dr Goh later bought shares from Peter, leaving Peter with a reduced holding. Dr Goh also entered into agreements with other shareholders to secure proxy voting rights, aiming to ensure that he retained control despite his family no longer being majority shareholders from September 2013 onwards. Despite these arrangements, Dr Goh alleged that the defendants refused to provide executed proxy forms for an extraordinary general meeting scheduled for 9 June 2015 (“the June EGM”), prompting his application for injunctive relief to restrain the defendants from calling meetings for certain purposes.
In parallel, the Company and its wholly owned subsidiary, AMH, brought a separate suit (Suit No 111 of 2016). The AM group alleged that Quikglow (incorporated by Dr Goh and Michelle) competed with the PPP laser brand clinics operated by AMH. The AM group’s causes of action included breaches of fiduciary and/or contractual duties by Dr Goh and Michelle, and conspiracy by lawful and/or unlawful means involving Dr Goh, Michelle, and Quikglow. The AM group also sought and obtained Mareva freezing relief against Dr Goh and disclosure orders, and later obtained leave to add PPP Investments as a plaintiff and to join additional defendants.
What Were the Key Legal Issues?
The first major legal issue concerned the standards for granting an injunction in a corporate governance context. Dr Goh sought to restrain RSP and related defendants from calling meetings of the Company for the purpose of altering share capital, including allotting and/or issuing shares and voting to alter share capital. The core question was whether the court should preserve the status quo pending the resolution of the substantive claims in the 2015 suit, and whether the evidence supported the necessary threshold for interlocutory relief.
The second major issue concerned the propriety and scope of Mareva-type relief in the AM group’s suit. Although the excerpt indicates that the AM group obtained a Mareva injunction and disclosure orders, and that Dr Goh later applied to set aside those orders, the legal question underlying such applications typically involves whether there is a sufficient risk of dissipation of assets and whether the freezing order is proportionate and justified on the evidence. The court also had to consider whether the injunctions and freezing relief were appropriately tailored to the alleged wrongdoing.
A third issue, reflected in the description of AM’s application and the setting aside application, concerned the interaction between equitable relief and alleged breaches of fiduciary or contractual duties, including restraints connected to competition and the use of services or personnel. The court had to assess whether the injunction granted to restrain Dr Goh and Michelle from joining Quikglow and engaging in similar business was supportable on the evidence and legal principles applicable to interim restraints.
How Did the Court Analyse the Issues?
Although the provided extract is truncated and does not include the full reasoning on each application, the judgment’s structure and the decisions described allow a lawyer to identify the analytical framework the court applied. In interlocutory injunction applications, Singapore courts generally require the applicant to demonstrate a serious question to be tried, that damages would not be an adequate remedy, and that the balance of convenience favours the grant of the injunction. In corporate disputes, the “status quo” consideration is often central: the court will consider whether the interim order is necessary to prevent irreparable harm or to avoid rendering the substantive proceedings nugatory.
In Dr Goh’s application, the court dismissed the injunction sought to restrain the defendants from calling meetings intended to alter share capital. This suggests that, on the evidence before the court, Dr Goh did not satisfy the threshold for the specific interim relief requested. The court likely scrutinised whether the alleged refusal to provide executed proxy forms and the claimed “grave danger” of removal from the board justified an order preventing the defendants from exercising corporate rights in relation to share capital. The court would also have considered whether the injunction was too broad or whether it would unduly interfere with corporate decision-making beyond what was necessary to preserve the status quo.
The court’s approach to the Mareva injunction and related setting aside application would have followed established principles governing freezing orders. A Mareva injunction is an exceptional remedy that requires evidence of a real risk that the defendant will dissipate assets or otherwise frustrate enforcement. The court would have assessed whether the AM group established a sufficiently strong prima facie case on the underlying claims (including allegations of breach of duties and conspiracy) and whether the risk of dissipation was supported by credible evidence. The fact that a Mareva injunction and disclosure orders were initially granted indicates that the court found the evidential threshold met at the time of the ex parte or early inter partes hearing.
When Dr Goh later applied to set aside the Mareva injunction and the injunction restraining competition, the court would have re-evaluated the evidence and the proportionality of the orders. In such applications, the court typically considers whether the applicant has shown that the original order should not have been granted, whether there has been a material change in circumstances, and whether the scope of the freezing order remains justified. The excerpt states that the setting aside application was dismissed, implying that the court remained satisfied that the freezing and restraint orders were warranted and that the defendants did not undermine the factual or legal basis for those orders.
Finally, the injunction restraining Dr Goh and Michelle from competing through Quikglow would have required the court to consider the nature of the alleged fiduciary or contractual obligations and whether an interim restraint was necessary to prevent ongoing or imminent harm. In disputes involving competition and the use of personnel or business opportunities, courts often examine whether there is a credible case that the defendants are acting in breach of duties owed to the company or in breach of contractual undertakings, and whether the interim restraint is no more than necessary to protect the applicant’s legitimate interests pending trial.
What Was the Outcome?
In the 2015 suit, Dr Goh’s application for an injunction (Summons No 1124 of 2016) to restrain the first to sixth defendants from calling meetings for the purpose of altering the Company’s share capital was dismissed. This meant that, pending the resolution of the substantive dispute, the defendants were not restrained from pursuing corporate actions relating to share capital alteration through meetings.
In the 2016 suit, the AM group’s earlier interim reliefs—namely the Mareva injunction and the injunction restraining competition—were not set aside. The court dismissed the setting aside application (Summons No 934 of 2016). The LawNet editorial note further indicates that related appeals were heard by the Court of Appeal in April 2017, with CA 114/2016 dismissed and CA 115/2016 allowed, while orders were made for CA 116/2016 without written grounds.
Why Does This Case Matter?
This case is significant for practitioners because it illustrates how Singapore courts manage urgent interlocutory relief in shareholder and corporate control disputes, where the practical consequences of interim orders can be substantial. Injunctions that interfere with corporate governance—such as restraining meetings or voting on share capital—are particularly sensitive. The dismissal of Dr Goh’s application underscores that courts will not lightly prevent shareholders or controllers from exercising corporate rights, especially where the applicant’s evidence and the balance of convenience do not justify the breadth of the restraint sought.
It also demonstrates the evidential and procedural importance of Mareva relief and disclosure orders. Freezing orders are powerful tools, and their continued validity depends on the applicant’s ability to show a real risk of dissipation and a credible underlying case. The court’s dismissal of the setting aside application indicates that, at least on the record before it, the AM group’s case met the necessary threshold and the orders were proportionate.
For law students and litigators, the case is also a useful study in how courts treat parallel proceedings and multiple interim applications. The dispute involved both (i) a governance/control narrative in the 2015 suit and (ii) a fiduciary/competition narrative in the 2016 suit. The court had to ensure that interim relief in one strand did not improperly prejudice the other, while still addressing immediate risks of harm and frustration of enforcement.
Legislation Referenced
- Companies Act (Singapore) — provisions relevant to corporate remedies and allegations of fraudulent trading (as referenced in the metadata)
Cases Cited
- [2016] SGHC 275 (as provided in the supplied metadata)
Source Documents
This article analyses [2016] SGHC 275 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.